


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-29. (Cancelled)

30. (new) A compound of general formula (I) :



wherein :

. R₁ represents an hydrogen atom, (C₁-C₆) alkyl, aryl, (C₁-C₆)alkylaryl, aryl(C₁-C₆)alkyl group, (C₃-C₆) alkenyl, or (C₃-C₆) alkenylaryl,

. R₇ represents a, substituted or not substituted, aryl or heteroaryl group,

when R₇ is a substituted aryl, it is preferably mono or bis substituted by the following groups : a (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₃-C₆)cycloalkyloxy, (C₁-C₆)alkyloxy, (C₃-C₆)alkenyloxy, aryloxy, acyl, halogen, trifluoromethyl, difluoromethyl, cyano, nitro, hydroxy, carboxamide, amino, (C₁-C₆)aminoalkyl, (C₁-C₆)aminodialkyl, NCOR₁₂ where R₁₂ is a (C₁-C₆)alkyl, (C₁-C₆)alkylaryl, aryl, or -CONR₁₃R₁₄ wherein R₁₃ and R₁₄,

independently from each other, are selected from the group consisting of a hydrogen atom, an (C₁-C₆)alkyl group, (C₃-C₆)alkenyl group, an alkylaryl, an alkenylaryl, and an aryl group,

. R₈ represents a hydrogen atom or a OR₁₀ group, wherein R₁₀ is a hydrogen atom, an (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₃-C₆) alkenyl, trifluoromethyl, difluoromethyl, an (C₃-C₆)alkenylaryl, aryl, or heterocyclic group, aromatic or not, having 1 to 3 heteroatoms chosen between O, N, S,

when R₁₀ is an aryl, it is preferably mono or bis substituted by the following groups : an hydrogen, (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, (C₃-C₆)cycloalkyloxy, (C₁-C₆)alkyloxy, (C₃-C₆)alkenyloxy, halogen, trifluoromethyl, difluoromethyl, cyano, nitro, hydroxy, carboxamide, amino, (C₁-C₆)aminoalkyl, (C₁-C₆)aminodialkyl, NCOR₁₂ where R₁₂ is a (C₁-C₆)alkyl, (C₁-C₆)alkylaryl, aryl, and -CONR₁₃R₁₄ wherein R₁₃ and R₁₄, independently from each other, are selected from the group consisting of a hydrogen atom, an (C₁-C₆)alkyl group, (C₃-C₆)alkenyl group, an alkylaryl, an alkenylaryl, and an aryl group,

. R_x represents an hydrogen atom, an halogen atom, a methyl, a methoxy, an acetyl, a trifluoromethyl, CN, COH or CONH₂ group,

. R_y represents an hydrogen, halogen atom, (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, aryl, arylalkyl, (C₃-C₆)cycloalkyloxy, COH, (C₁-C₆)alkyloxy, alkenyl, (C₃-C₈)alkenyloxy, alkynyl, alkynyloxy, acyl, halogen, trifluoromethyl, difluoromethyl, trifluoromethoxy, difluoromethoxy, cyano, nitro, hydroxy, carboxamide, amino, (C₁-C₆)aminoalkyl, (C₁-C₆)aminodialkyl, NHCOR₁₂ where R₁₂ is a (C₁-C₆)alkyl, (C₁-C₆)alkyloxy, hydroxy, (C₁-C₆)alkylaryl, aryl, or -CONR₁₃R₁₄ wherein R₁₃ and R₁₄, independently from each other,

are selected from the group consisting of a hydrogen atom, an (C₁-C₆)alkyl group, an (C₂-C₆)alkenyl group, an alkynyl, an alkylaryl, an alkenylaryl, an alkynylaryl, and an aryl group,

with the proviso that when R₈ is an hydrogen atom, then R_X or R_Y is different from hydrogen,

or a pharmaceutically acceptable salt thereof.

31. (new) The compound of formula (I) according to claim 30, wherein R₈ is an hydrogen atom, a alkoxy, preferably methoxy or ethoxy, or aryloxy, preferably phenoxy group.

32. (new) The compound of formula (I) according to claim 30, wherein at least one of R_X and R_Y is different from hydrogen.

33. (new) The compound of formula (I) according to claim 30, wherein R_Y is an hydrogen atom and R_X is different from hydrogen.

34. (new) The compound of formula (I) according to claim 30, wherein one of R_X and R_Y, different from hydrogen, is on position 3 of the phenyl group represented in formula (I).

35. (new) The compound of formula (I) according to claim 30, wherein R_x , different from hydrogen, is on position 3 of the phenyl group represented in formula (I).
36. (new) The compound of formula (I) according to claim 30, wherein R_x represents a CONH_2 , CN , or COCH_3 group, preferably on position 3 or 4 of the phenyl group represented in formula (I).
37. (new) The compound of formula (I) according to claim 30, wherein R_y represents H, an halogen atom, CF_3 , $(\text{C}_1\text{-C}_6)\text{aminoalkyl}$, $(\text{C}_1\text{-C}_6)\text{aminodialkyl}$, $-\text{NHCOR}_{12}$, $-\text{CONH}_2$, a $(\text{C}_1\text{-C}_6)\text{alkyloxy}$ group or a $(\text{C}_1\text{-C}_6)\text{alkyl}$ group, preferably hydrogen.
38. (new) The compound of formula (I) according to claim 30, wherein R_1 represents an hydrogen atom, an alkyl group, preferably methyl, ethyl, or propyl, an alkenyl group, preferably propenyl, or arylalkyl group.
39. (new) The compound of formula (I) according to claim 30, wherein R_7 is a furan group, said group is preferably a furan-2-yl.
40. (new) The compound of formula (I) according to claim 30, wherein R_7 is an unsubstituted aryl group, preferably unsubstituted phenyl group.

41. (new) The compound of formula (I) according to claim 30, wherein R₇ is a substituted aryl or heteroaryl group, preferably a substituted phenyl group.

42. (new) The compound of formula (I) according to claim 30, wherein R₇ is a substituted aryl or heteroaryl group, preferably a substituted phenyl group, and said substituted aryl or heteroaryl group is substituted with one or two, identical or different, substituents selected in the group consisting of halogen, amino, aminoacyl, CONH₂, (C₁-C₆)alkyl, aryloxy, and (C₁-C₆)alkyloxy.

43. (new) The compound of formula (I) according to claim 30, wherein R₇ is a substituted aryl or heteroaryl group, preferably a substituted phenyl group, and said substituted aryl or heteroaryl group is substituted with alkoxy which is a methoxy or ethoxy group.

44. (new) The compound of formula (I) according to claim 30, wherein R₇ is a substituted phenyl group substituted by at least one group on position ortho, which is preferably an alkoxy group.

45. (new) The compound of formula (I) according to claim 30, wherein R₇ is a substituted phenyl group selected in the group consisting of 4-methoxy-phenyl, 4-fluoro-phenyl, 2-methoxy-phenyl, 2-chloro-phenyl, 4-chloro-phenyl, 3-chloro-phenyl, 3-methoxy-phenyl, 2,5-dimethoxy-phenyl, 2,6-dimethoxy-phenyl, 4-benzamide, 4-

cyanophenyl, 2,4-dimethoxy-phenyl, 4-carboxamide-phenyl, 4-acetyl-phenyl, 2-isopropoxy-phenyl, 2-phenoxy-phenyl, and 3,4-dimethoxy-phenyl groups.

46. (new) A compound selected in the group consisting of :

3-(8-Methoxy-1-methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzonitrile

3-[7-(4-Fluoro-phenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzonitrile

3-[8-Methoxy-7-(2-methoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzonitrile

3-[8-Methoxy-7-(4-methoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzonitrile

3-[7-(2-Chloro-phenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzonitrile

3-[7-(3-Chloro-phenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzonitrile

3-[7-(4-Chloro-phenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzonitrile

3-(7-Furan-2-yl-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzonitrile

3-(1-Methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzonitrile

3-[8-Methoxy-7-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-
benzonitrile

3-(1-Methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzonitrile

3-[7-(2-Methoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-
benzonitrile

3-[7-(3-Methoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-
benzonitrile

3-[7-(4-Methoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-
benzonitrile

3-[7-(2,5-Dimethoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-
benzonitrile

3-[7-(2,6-Dimethoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-
benzonitrile

3-[7-(2,4-Dimethoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-
benzonitrile

8-Ethoxy-1-ethyl-5,7-diphenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one

3-(8-Methoxy-1-methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-
benzamide

3-[7-(4-Fluoro-phenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]
diazepin-5-yl]-benzamide

3-[8-Methoxy-7-(2-methoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]
diazepin-5-yl]-benzamide

3-[8-Methoxy-7-(4-methoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-
benzo[e][1,4]diazepin-5-yl]-benzamide

3-[7-(2-Chloro-phenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-
5-yl]-benzamide

3-[7-(3-Chloro-phenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-
5-yl]-benzamide

3-[7-(4-Chloro-phenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-
5-yl]-benzamide

3-(7-Furan-2-yl-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-
benzamide

3-(1-methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzamide

3-[7-(2-methoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-
benzamide

3-[7-(3-methoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-
benzamide

3-[7-(4-methoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-
benzamide

3-[7-(2,5-Dimethoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-
benzamide

3-[7-(2,6-Dimethoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide

3-[7-(2,4-Dimethoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide

3-(8-Methoxy-7-(4-benzamide)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzamide

3-[1-Hexyl-8-methoxy-7-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzonitrile

3-[8-Methoxy-7-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide

3-[8-Methoxy-7-(2-methoxy-phenyl)-2-oxo-1-propyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzonitrile

3-[8-Methoxy-7-(2-methoxy-phenyl)-2-oxo-1-phenethyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzonitrile

3-[1-Benzyl-8-methoxy-7-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzonitrile

5-(3-Chloro-phenyl)-1-methyl-7-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one

5-(2-Chloro-phenyl)-1-methyl-7-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one

5-(4-Chloro-phenyl)-1-methyl-7-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one

3-(8-Methoxy-1-methyl-2-oxo-7-(4-cyanophenyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzonitrile.

3-[1-Benzyl-8-methoxy-7-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide

3-[8-Methoxy-7-(2-methoxy-phenyl)-2-oxo-1-propyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide

3-[8-Methoxy-7-(2-methoxy-phenyl)-2-oxo-1-phenethyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide

3-[1-Hexyl-8-methoxy-7-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide

3-[7-(4-Acetyl-phenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzonitrile

3-[7-(4-Acetyl-phenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide

5-(4-Methoxy-phenyl)-1-methyl-7-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one

5-(2-Methoxy-phenyl)-1-methyl-7-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one

3-(7-Furan-2-yl-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzonitrile

3-[7-(3,4-Dimethoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzonitrile

3-[7-(3,4-Dimethoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide

5-(3,5-Dichloro-phenyl)-1-methyl-7-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one

5-(3,4-Dichloro-phenyl)-1-methyl-7-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one

5-(4-Fluoro-phenyl)-1-methyl-7-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one

5-(3-Acetyl-phenyl)-1-methyl-7-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one

1-Methyl-7-phenyl-5-(3-trifluoromethyl-phenyl)-1,3-dihydro-benzo[e][1,4]diazepin-2-one

1-Methyl-5-(4-methyl-3-nitro-phenyl)-7-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one

1-Methyl-7-phenyl-5-(4-trifluoromethoxy-phenyl)-1,3-dihydro-benzo[e][1,4]diazepin-2-one

5-(3-Bromo-phenyl)-8-methoxy-1-methyl-7-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one

3-[7-(2-Isopropoxy-phenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzonitrile

5-(3,4-Dimethoxy-phenyl)-1-methyl-7-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one

1-Methyl-5-(3-nitro-phenyl)-7-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one

5-(3-Hex-1-ynyl-phenyl)-8-methoxy-1-methyl-7-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one

{3-[3-(8-Methoxy-1-methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-phenyl]-prop-2-ynyl}-carbamic acid tert-butyl ester

5-(3-Amino-phenyl)-1-methyl-7-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one

3-(1-Methyl-2-oxo-8-phenoxy-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzonitrile

3-[7-(2-Methoxy-phenyl)-1-methyl-2-oxo-8-phenoxy-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzonitrile

3-[7-(2-Chloro-phenyl)-1-methyl-2-oxo-8-phenoxy-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzonitrile

3-(1-Methyl-2-oxo-8-phenoxy-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzamide

3-[7-(2-Chloro-phenyl)-1-methyl-2-oxo-8-phenoxy-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide

3-[7-(2-Methoxy-phenyl)-1-methyl-2-oxo-8-phenoxy-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide

7-(2,6-Dimethoxy-phenyl)-5-(4-methoxy-phenyl)-1-methyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one

8-Methoxy-5-(4-methoxy-phenyl)-7-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one

7-(2,6-Dimethoxy-phenyl)-1-methyl-5-(4-methyl-3-nitro-phenyl)-1,3-dihydro-benzo[e][1,4]diazepin-2-one

3-[7-(2-Isopropoxy-phenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide

5-(3-Methoxy-phenyl)-1-methyl-7-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one

5-(3-Bromo-phenyl)-8-methoxy-7-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one

3-[7-(2-Chloro-6-methoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzonitrile

3-[7-(5-Chloro-2-methoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzonitrile

3-[7-(2-Chloro-6-methoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide

3-[7-(5-Chloro-2-methoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide

3-(2-Oxo-7-phenyl-8-trifluoromethoxy-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzonitrile

3-(1-Methyl-2-oxo-7-phenyl-8-trifluoromethoxy-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzonitrile

3-(1-Methyl-2-oxo-7-phenyl-8-trifluoromethoxy-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzamide

3-[1-Methyl-2-oxo-7-(2-phenoxy-phenyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzonitrile

3-[7-(2,6-Dimethoxy-phenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzonitrile

3-[8-Methoxy-1-methyl-2-oxo-7-(2-phenoxy-phenyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzonitrile

3-[1-Methyl-2-oxo-7-(2-phenoxy-phenyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide

3-[7-(2,6-Dimethoxy-phenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide

3-[8-Methoxy-1-methyl-2-oxo-7-(2-phenoxy-phenyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide

8-Methoxy-1-methyl-7-phenyl-5-[3-(4-phenyl-butyl)-phenyl]-1,3-dihydro-
benzo[e][1,4]diazepin-2-one

8-Methoxy-5-[3-(3-methoxy-prop-1-ynyl)-phenyl]-1-methyl-7-phenyl-1,3-dihydro-
benzo[e][1,4]diazepin-2-one

{3-[4-(8-Methoxy-1-methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-
phenyl]-prop-2-ynyl}-carbamic acid tert-butyl ester

8-Methoxy-1-methyl-7-phenyl-5-(4-phenylethynyl-phenyl)-1,3-dihydro-
benzo[e][1,4]diazepin-2-one

8-Methoxy-5-[4-(3-methoxy-prop-1-ynyl)-phenyl]-1-methyl-7-phenyl-1,3-dihydro-
benzo[e][1,4]diazepin-2-one

5-(3,4-Dichloro-phenyl)-7-(2,6-dimethoxy-phenyl)-1-methyl-1,3-dihydro-
benzo[e][1,4]diazepin-2-one

7-(2,6-Dimethoxy-phenyl)-5-(4-fluoro-phenyl)-1-methyl-1,3-dihydro-
benzo[e][1,4]diazepin-2-one

5-(3,4-Dimethoxy-phenyl)-7-(2,6-dimethoxy-phenyl)-1-methyl-1,3-dihydro-
benzo[e][1,4]diazepin-2-one

5-(2-Bromo-phenyl)-8-methoxy-7-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one

8-Methoxy-5-[3-(3-methoxy-propyl)-phenyl]-1-methyl-7-phenyl-1,3-dihydro-
benzo[e][1,4]diazepin-2-one

5-(2-Bromo-phenyl)-8-methoxy-1-methyl-7-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-
one

5-(4-Hex-1-ynyl-phenyl)-8-methoxy-1-methyl-7-phenyl-1,3-dihydro-

benzo[e][1,4]diazepin-2-one

8-Methoxy-5-[4-(3-methoxy-propyl)-phenyl]-1-methyl-7-phenyl-1,3-dihydro-

benzo[e][1,4]diazepin-2-one

{3-[4-(8-Methoxy-1-methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-phenyl]-propyl}-carbamic acid tert-butyl ester

8-Methoxy-5-(4-methoxy-phenyl)-7-(2-methoxy-phenyl)-1-methyl-1,3-dihydro-

benzo[e][1,4]diazepin-2-one

7-(2,6-Dimethoxy-phenyl)-8-methoxy-5-(4-methoxy-phenyl)-1-methyl-1,3-dihydro-

benzo[e][1,4]diazepin-2-one

7-(2,5-Dimethoxy-phenyl)-8-methoxy-5-(4-methoxy-phenyl)-1-methyl-1,3-dihydro-

benzo[e][1,4]diazepin-2-one

7-(2-Fluoro-6-methoxy-phenyl)-8-methoxy-5-(4-methoxy-phenyl)-1-methyl-1,3-dihydro-

benzo[e][1,4]diazepin-2-one

8-Methoxy-5-(4-methoxy-phenyl)-1-methyl-7-(2-phenoxy-phenyl)-1,3-dihydro-

benzo[e][1,4]diazepin-2-one

5-(4-Bromo-phenyl)-8-methoxy-1-methyl-7-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-

one

5-(4-Bromo-phenyl)-8-methoxy-7-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one

7-(2,6-Dimethoxy-phenyl)-1-methyl-5-m-tolyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one.

47. (new) A compound selected in the group consisting of :

3-[7-(2,6-dimethoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide, 3-[7-(2,5-dimethoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide, 3-[8-methoxy-7-(4-methoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide, 3-[8-methoxy-7-(2-methoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide, 3-[7-(2-chloro-phenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide, 3-(8-methoxy-1-methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzamide, 7-(2,6-Dimethoxy-phenyl)-5-(4-methoxy-phenyl)-1-methyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one, 3-[7-(2-Chloro-6-methoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide, 3-[7-(2,6-Dimethoxy-phenyl)-8-methoxy-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide, 3-[8-Methoxy-1-methyl-2-oxo-7-(2-phenoxy-phenyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide, 5-(3,4-Dichloro-phenyl)-7-(2,6-dimethoxy-phenyl)-1-methyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one, 7-(2,6-Dimethoxy-phenyl)-1-methyl-5-m-tolyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one and 7-(2,6-Dimethoxy-phenyl)-8-methoxy-5-(4-methoxy-phenyl)-1-methyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one.

48. (new) A compound selected in the group consisting of :

3-[7-(2,5-Dimethoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide, 3-[7-(2,6-Dimethoxy-phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide, 3-[7-(2,6-Dimethoxy-phenyl)-8-methoxy-1-

methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl]-benzamide, 7-(2,6-Dimethoxy-phenyl)-5-(4-methoxy-phenyl)-1-methyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one, 7-(2,6-Dimethoxy-phenyl)-5-(4-fluoro-phenyl)-1-methyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one, and 7-(2,6-Dimethoxy-phenyl)-8-methoxy-5-(4-methoxy-phenyl)-1-methyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one.

49. (new) A pharmaceutical composition comprising at least one compound as defined in claim 30, and a pharmaceutically acceptable vehicle or support.

50. (new) A method for the treatment of diseases associated with abnormal regulation of intracellular cAMP and/or cGMP rate, comprising administering to a patient in need of such treatment an effective amount of at least one compound of general formula (I) as defined in claim 30.

51. (new) The method according to claim 50, for the treatment of diseases of the central nervous system, especially connected with an abnormal regulation of neurotransmitter effect or a release deficiency of one of the neurotransmitters.

52. (new) The method according to claim 50, for the treatment of a disease selected in the group consisting of depression, schizophrenia, autism, anxiety, bipolar disorder, attention deficit hyperactivity disorder (ADHD), sleeping disorders, obsessive

compulsive disorders (OCD), Post Traumatic Stress Disorder (PTSD) fibromyalgia, Tourette's syndrome, drug or alcohol dependence, epilepsy, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, obesity, and Lewy body dementia.

53. (new) The method according to claim 50, for the treatment of a disease of the peripheral nervous system or peripheral organs.

54. (new) The method according to claim 50, for the treatment of a disease selected in the group consisting of reduced natriuria pathologies, acute renal or liver failure, liver dysfunction, and pathologies due to or involving prolactin release dysfunction, such as restless leg syndrom, rheumatic, allergic or autoinflammatory disorders, such as rheumatoid arthritis, rhinitis, and asthma.

55. (new) The method according to claim 50, for the treatment of, central or peripheral, acute or chronic diseases.

56. (new) The method according to claim 50, for the treatment of memory deficiency or cognitive disorders.

ABARGHAZ et al.

U.S. National Phase of PCT/IB2004/004362

57. (new) The method according to claim 50, for the treatment of neuro-degenerative diseases.

58. (new) The method according to claim 50, for the treatment of obesity.